Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up
Authors' conclusion
Lenvatinib provided durable disease control in patients with RAI-R DTC. Older age at treatment initiation and bone metastasis were independent determinants of survival and may help guide risk stratification and treatment timing in clinical practice.
Study context
- Population
- Patients with progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with lenvatinib at a single institution between 2015 and 2024; patients with anaplastic or medullary thyroid carcinoma and those treated for less than six months excludedpatients analyzed
- Participants
- 97 patients
- Exposure
- Prognostic factors (age, bone metastasis) for progression-free survival (PFS) and overall survival (OS), assessed using Cox proportional hazards models
- Outcome
- Progression-free survival (PFS) and overall survival (OS)
- Follow-up
- Median 36 months
Methodological detailssingle institution, real-world, extended follow-up, Cox proportional hazards models, Kaplan-Meier method
- Single institution
- Real-world
- Extended follow-up
- Cox proportional hazards models
- Kaplan-Meier method
Main finding
As reported in the abstract
median follow-up of 36 months
Median PFS
25 months
95% CI 21–31
Median OS
59 months
95% CI 45–82
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| PFS by age (multivariate analysis)Older age an independent predictor of shorter PFS · multivariate analysis | HR 1.34 per decade of age, event not clearly stated | P < 0.01 |
| OS by age (multivariate analysis)Older age an independent predictor of shorter OS · multivariate analysis | HR 1.63 per decade of age, event not clearly stated | P < 0.005 |
| OS and PFS by bone metastasis (multivariate analysis)Independently associated with worse OS · multivariate analysis | HR 2.25, event not clearly stated | P < 0.05 |
Objective response rate and disease control rate
- Objective response rate
- 58%
- Disease control rate
- 97%
OS and PFS by bone metastasis (multivariate analysis)
- Bone metastasis not independently associated with PFS
Baseline characteristics · treatment initiation
- Median age at treatment initiation
- 68 years
- Patients with bone metastases
- 38%
Age cutoffs (receiver operating characteristic analyses)
- Suggested age cutoffs
- ≈70 years
OS by bone metastasis among older patients
- Bone metastasis associated with significantly poorer OS among older patients
- Subgroup
Original publication
Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up. Eur Thyroid J. Published 12 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →